National Centre for Sport and Exercise Medicine
Loughborough, LE113TU, United Kingdom
NCT Number: NCT04761081
Being south Asian or centrally obese may be associated with an increased risk of inflammation. The investigators are seeking to investigate whether this is the case by recruiting white European and south Asian men who are lean or have central obesity. Further, the investigators wish to investigate whether physical activity influences the associations.
Looking for future studies?
Notify Me18 year–60 year
Male
Observational
Loughborough, LE113TU, United Kingdom
Central obesity is associated with an increased risk of cardiovascular disease. Further, south Asians have been shown to be at an increased risk of cardiovascular disease compared to white Europeans.
Cardiovascular disease is underpinned by inflammation. Evidence suggests that people with obesity have a more pro-inflammatory and pro-migratory monocyte profile compared with individuals who are lean. The excessive monocyte migration contributes to metabolic dysfunction over time, increasing the risk of chronic disease. However, there is no evidence in south Asians.
One modifiable risk factor which may be able to influence this is physical inactivity, with higher levels of physical activity being associated with reduced inflammation. However, although south Asians are more at risk of cardiovascular disease than white Europeans, evidence suggests south Asians are also less physically active than white Europeans.
The investigators are looking to recruit south Asian and white European men who are lean or have central obesity to investigate 1) is there an association between ethnicity and the tethering and migration of pro-inflammatory monocytes? 2) is there an association between central obesity and the tethering and migration of pro-inflammatory monocytes, and is there an interaction with ethnicity? 3) do higher levels of physical activity influence the tethering and migration of pro-inflammatory monocytes, and is this influenced by ethnicity or central obesity?
To investigate this, the investigators are looking to recruit south Asian and white European men who are either centrally obese or lean. The investigators require 1 blood sample and the participants to wear an activity monitor for 7 days.
Peripheral blood mononuclear cells (PBMCs) will be isolated from the whole blood sample. Then, the investigators will quantify the migratory capacity of PBMCs to a fixed chemokine gradient over time. Further, the investigators will phenotype the monocytes to indicate the characteristics of the monocytes that migrate towards the chemokine mix.
The activity monitor will quantify habitual physical activity, which will be used in the statistical analyses to investigate whether physical activity may influence the response.
It is important to investigate as it will further scientific knowledge on the underpinnings of chronic disease and enable a better understanding on the role of physical activity to potentially reduce the risk.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
7 days habitual physical activity via accelerometry (ActiGraph GT3x). Specifically steps per day, light physical activity (minutes per day), and moderate to vigorous physical activity (minutes per day).
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry. Presented as cells/uL.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry. Presented as cells/uL.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry. Presented as cells/uL.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry. Presented as cells/uL.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry. Presented as cells/uL.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry. Presented as cells/uL.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via flow cytometry.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Fasted concentration of total cholesterol. Presented as mmol/L.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Fasted concentration of high-density lipoprotein cholesterol. Presented as mmol/L.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Fasted concentration of low-density lipoprotein cholesterol. Presented as mmol/L.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Fasted concentration of triacylglycerol. Presented as mmol/L.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Fasted concentration of glucose. Presented as mmol/L.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Fasted concentration of c-reactive protein. Presented as mg/L.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Fasted concentration of interleukin-6. Presented as pg/mL.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Fasted concentration of non-esterified free fatty acids. Presented as mmol/L.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Body fat percentage determined via bioelectrical impedance analysis. Presented as percentage.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Determined via bioelectrical impedance analysis. Presented in kilograms.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Waist circumference. Presented as centimetres.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Presented as mmHg.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Presented as mmHg.
Time frame: Over 7 days +/- the assessment day
Time spent participating in light physical activity. Presented as minutes per day.
Time frame: Over 7 days +/- the assessment day
Time spent participating in moderate-to-vigorous physical activity. Presented as minutes per day.
Time frame: Over 7 days +/- the assessment day
Total daily steps. Presented as steps per day.
Loughborough University
Other
Is Physical Activity Associated With the Tethering and Migration of Pro-inflammatory Monocytes in White European and South Asian Males With and Without Central Obesity.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02900898
Arthritis, Arthritis, Rheumatoid
Mexico City, Tlalpan, Mexico
View Trial DetailsNCT03654105
Behavior, Diet Modification
Milan, Italy
View Trial DetailsNCT07009223
Behavior, Behavioral Symptoms
Brescia, Italy
View Trial DetailsNCT06810271
Behavior, Delayed Onset Muscle Soreness (DOMS)
Toronto, Ontario, Canada
View Trial Details